SUPERA: Supporting Peer Interactions to Expand Access to Digital Cognitive Behavioral Therapy for Spanish-speaking Safety-Net Patients in Primary Care
Sponsor: University of California, Irvine
Trial Details
| Condition | Depression, Anxiety |
| Intervention | Supported dCBT; Unsupported dCBT |
| Phase | NA |
| Status | Unknown |
| Participants | 426 |
| Est. Completion | 31 Dec 2027 |
| Last Updated | 19 May 2026 |
Primary Outcome
Change in Depression at 8 Weeks; Change in Anxiety at 8 Weeks
Eligibility Criteria
Inclusion Criteria
Inclusion Criteria: 1. PHQ-9 ≥ 10 or GAD-7 ≥ 8 2. Has access to the Internet via smartphone and/or broadband at home, and basic level of technological literacy or willingness to undergo a brief technology use training 3. ≥18 years of age 4. Preference for receiving medical care in Spanish 5. Not in concurrent psychotherapy 6. If currently taking an antidepressant medication, patient must have been on a stable dose for at least 6 weeks, and have no plans to change the dose. We will permit patients on antidepressants to enter the study, as this will increase generalizability. Antidepressant status will be monitored at each assessment to control for those effects, if necessary. Exclusion Criteria: 1. Currently receiving psychotherapy, as this treatment will be offered as a frontline treatment for depression and anxiety, however, patients are allowed to be referred to treatment while participating in this study and initiation of treatment will be monitored and considered in analyses 2. Visual, hearing, voice, or motor impairment or illiteracy that would prevent completion of study procedures 3. Diagnosis of a psychotic disorder, bipolar disorder, dissociative disorder, or substance use disorder 4. Severe suicidality (as assessed by expressing suicidal ideation, plan, and intent). Although procedures with back-up plans are in place for patients who develop suicidality (see Human Subjects Section), patients assessed with severe suicidality will be referred to more-intensive treatment resources.
Trial Sites
Countries
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service